Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.55 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320593 | 0.89 | SYK (0.59) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320682 | 0.87 | SYK (0.59) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320423 | 0.86 | SYK (0.60) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320705 | 0.84 | SYK (0.60) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320573 | 0.84 | SYK (0.58) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320869 | 0.84 | SYK (0.75) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320852 | 0.83 | SYK (0.57) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320266 | 0.82 | SYK (0.59) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14320985 | 0.82 | SYK (0.62) | SYKJAK2BTKMAPTMEN1 | |
| SCHEMBL14321376 | 0.82 | SYK (0.57) | SYKJAK2BTKMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | claimed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | SYK 11/4885JAK2 60/4885BTK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.